BACKGROUND: Isolated pulmonary amyloidosis is a very rare disease.
A myloidosis is the name given to a group of conditions in which abnormal protein material (amyloid) is deposited in the extracellular matrix resulting in disordered structure and dysfunction of tissues and organs. Amyloidosis is caused by the abnormal folding of proteins, and the amyloid is made up primarily of protein fibrils. [1, 2] Primary systemic amyloidosis is a heterogenous disease with varied manifestations, and can involve the kidneys, gastrointestinal tract, skin, respiratory system, heart, and other organs; however, forms of localized amyloidosis affecting only one organ system are known. [1] The incidence of amyloidosis is low, [2] and that of amyloidosis with involvement of only the respiratory system is extremely low. [3] There is no gender difference in the incidence of primary amyloidosis, and the disease typically occurs in individuals >50 years of age. The clinical presentations of amyloidosis are protean, and symptoms are non-specific, which can make arriving at a diagnosis difficult. [1, 2] The condition can be an incidental finding, chronic or progressive, with death occurring within months of diagnosis in severe cases. [1, 2] No definitive treatment is available, and common treatments included glucocorticoid, melphalan, and colchicines. [1, 2] Manifestations of isolated pulmonary amyloidosis include dyspnea, cough, and hemoptysis and clinical findings are as varied as isolated pulmonary nodules, mediastinal lymphadenopathy, and non-specific radiographic findings. [4] [5] [6] Diseases such as pulmonary tuberculosis, connective tissue disease, malignancy, and multiple myeloma need to be ruled-out in order to avoid delaying treatment.
Because of the rarity of amyloidosis involving only the respiratory system, we searched the records of our hospital over a 21-year period and identified 13 patients with pathologically proven amyloidosis involving only the respiratory system. The purpose of this study is to present the clinical characteristics, pathological findings, treatments, and outcomes of these patients.
Methods
The medical records of 13 patients with pathologically proven amyloidosis and respiratory system involvement treated at our hospital from January 1990 to May 2011 were retrospectively reviewed. Patient demographic and clinical characteristics including gender, age, disease course, age of onset, clinical manifestations, laboratory findings, imaging findings, and pathological findings were recorded for analysis. This study was approved by the Institutional Review Board of our hospital, and because of its retrospective nature the requirement of informed consent was waived.
Results

Patients
There were 9 males and 4 females with a mean age of 54.7 years (range, 45-72 years) included in the analysis. The mean duration from symptoms onset to confirmed pathological diagnosis was 11.2 months (range, 1-51 months). The mean course of disease was 46.5 months (range, 5 months-15 years). Patient demographic and clinical characteristics are summarized in Table 1 .
The clinical manifestations at presentation included cough (n = 10), expectoration (n = 8), hemoptysis (n = 4), chest tightness (n = 12), dyspnea (n = 10), chest pain (n = 3), intermittent fever (n = 5), and body weight loss (n = 2). Superficial lymph node enlargement was not found in any patient. The respiratory sounds were reduced and dullness was noted on percussion in 2 patients, wheezing on auscultation was found on inhalation in 6 patients, and moist rales were found in 4 patients.
Enlargement of the liver and spleen was absent in all patients, and work-up for tuberculosis, syphilis, chronic renal disease, hypergammaglobulinemia, rheumatoid arthritis, malignancies, and multiple myeloma was negative in all patients.
Laboratory examination
All patients were negative for HIV. The mean peripheral white blood cell (WBC) count was 6.2 ± 1.9×10 9 /L (neutrophils, 0.61 ± 0.05%); platelet count, 245 ± 39×10 9 /L; hemoglobin (Hb), 12.1 ± 1.6 g/L; and erythrocyte sedimentation rate (ESR) was 22 ± 8 mm/h. All patients had normal kidney and liver function testing, and normal serum electrolyte levels. Bone marrow examination was done in 2 patients, and was normal in both.
Imaging examinations
Abdominal ultrasonography did not reveal enlargement of the liver, spleen, or retroperitoneal lymph nodes in any patients. Chest radiograph findings were non-specific in all patients. Computed tomography (CT) or magnetic resonance imaging (MRI) revealed rugged mucosa in the trachea and adjacent major main bronchus resulting in tracheal stenosis in 2 patients and bronchial stenosis with atelectasis in 5 patients [ Figure 1a and b]. Lung consolidation was found in 1 patient [ Figure 2 ]. Nodular shadows in the lung were 
Bronchoscopy
Bronchoscopy was performed in all patients, and in 7 the mucosa of trachea and bronchi was rugged and nodular deposits were noted. Congestion and edema were also found in the mucosa, which was susceptible to bleeding on touching [ Figure 4 ].
Pathological examination
Bronchoscopic biopsy was performed in 7 patients, thoracoscopic biopsy in 1, percutaneous lung biopsy in 1, and wedge resection in 2. Two patients underwent mediastinoscopic biopsy of lymph nodes and thoracoscopic biopsy of pleura simultaneously. Pathological examination under a light microscopy and hematoxylin and eosin (H&E) staining revealed homogeneous, pink eosinophilic amyloid without cellular structure, and Congo red-stained tissue exhibited saffron yellow substances under light microscopy and red-green birefringence under polarizing microscopy [ Figure 5 ].
Treatment and prognosis
One of the two patients with endotracheal amyloidosis received endotracheal stenting and was stable at 3-years follow-up. The other one died of respiratory failure 4 years later. Three of five patients who were diagnosed with endobronchial amyloidosis received thoracotomy with lobectomy, and two were stable at 5-years follow-up and 15-years follow-up, respectively, but one developed recurrence 9 months later and died of pneumonia and respiratory failure 18 months after surgery. The other two patients with endobronchial amyloidosis were only treated with glucocorticoid and antibiotics, and one was stable at 3-years follow-up and one died of pneumonia and respiratory failure 3 years later.
Two patients with solitary lung nodule underwent wedge resection by thoracotomy and thoracoscopy, respectively, and were followed up for 3.5 years and 8 years without recurrence. One patient with multiple nodules treated with glucocorticoid and antibiotics died of respiratory failure and pneumonia one year later. One patient with enlarged mediastinal lymph node and bilateral pleural effusion underwent glucocorticoid and methotrexate treatment, but died of pneumonia 9 months later. The other patient with enlarged mediastinal lymph node and bilateral pleural effusion took traditional Chinese medicine, but died 5 months later. One patient with massive pulmonary consolidation [ Figure 2a ] was treated with glucocorticoid, melphalan and antibiotics; the lesion resolved 2 months later [ Figure 2b ] and at 1.5 years follow-up he was alive and well.
Discussion
Amyloidosis can be primary or secondary to other diseases including tuberculosis, syphilis, chronic renal disease, hypergammaglobulinemia, rheumatoid arthritis, malignancies, and multiple myeloma. [1, 2] Secondary amyloidosis seldom involves the lungs, but primary systemic amyloidosis frequently involves multiple systems including the heart, gastrointestinal tract, kidneys, and skin. [1, 2] Primary amyloidosis with involvement of only 1 system (localized amyloidosis) is uncommon, and disease with only respiratory system involvement alone is rare. [7] [8] [9] [10] [11] In patients with primary respiratory amyloidosis, amyloid is deposited in the pulmonary parenchyma and submucosa of the bronchi and trachea, pleura and lymph nodes in the mediastinum, and hilum of lungs. [11] Utz et al. [7] retrospectively analyzed the clinical record of patients seen at the Mayo Clinic over a 13-year period (1980-1993) , and of 55 patients with pathologically proven amyloidosis only 11 had the disease confined to the respiratory system. Primary pulmonary amyloidosis is classified into 4 types according to the site of the lesions [7] : tracheobronchial amyloidosis; nodular amyloidosis; infiltrating interstitial amyloidosis, and lymph node amyloidosis. Tracheobronchial amyloidosis is the most frequently seen in clinical practice, and the clinical manifestations included dyspnea, chest tightness, cough, expectoration, and hemoptysis. [7, 8] Chest radiographs and CT show increased lung markings, obstructive pneumonia and atelectasis, localized or diffuse stenosis of the trachea, thickened trachea and bronchus and nodular shadows in the lumen with occasional calcifications. Bronchoscopy shows single or multiple protrusions or generalized thickening of the bronchial wall and bronchial stenosis. The smooth protrusions have no nodules, are of different sizes, and are susceptible to bleeding on touch. Occasionally, the protrusions may obstruct the bronchus resulting in secondary infection. In some cases, the whole submucosa of the bronchus is infiltrated with amyloid substance leading to bronchial stenosis. In the present study, 7 patients developed tracheobronchial stenosis (53.8%) and their clinical manifestations were similar to previously reported.
Patients with nodular amyloidosis usually have a cough or hemoptysis, and imaging findings show single or multiple nodules or patchy shadows, and involvement of other organs is seldom found. [12] In the present study, 3 patients had nodular amyloidosis, 2 of whom received surgical resection of solitary nodular lesions.
Infiltrating interstitial amyloidosis is characterized by massive deposition of amyloid substances in small blood vessels and the pulmonary interstitium. [13] High resolution CT shows thickening of interlobular septum, network-like blurred shadows, or multiple subpleural nodules (2-4 mm in size). Lymph node amyloidosis is characterized by deposition of amyloid substances in lymph nodes in the mediastinum and pulmonary hilum. [14] The condition is rarely seen in patients without systemic amyloidosis, and was found in only 2 patient in the present study.
Pathological examination of a tissue specimen is the gold standard for the diagnosis of amyloidosis. Under a light microscope, hematoxylin & eosin (H&E) staining shows homogeneous, pink amyloid substances without cellular structure that are usually accompanied by fibrosis, and characteristic red-green birefringence is seen under polarizing microscopy in Congo red-stained tissue. [2] The edge of cord or mass-like amyloid substances were blur and their outlines become light gradually.
The principles in the treatment of amyloidosis are to inhibit the synthesis of amyloid and its extracellular deposition, reduce the production of amyloid precursors, and promote the degradation of amyloid. [1, 2] To date, there are no completely effective therapies and the effectiveness of glucocorticoid, vitamin E, colchicine, and other drugs is not clear. [11] Resection of intratracheal and bronchial lesions with Nd-YAG laser or endoscopic clipping has been reported. [10] External beam radiation therapy has also been attempted with promising results, in spite of the underlying mechanisms. [15] Systemic chemotherapy consisting of 0.15 mg/ kg/d melphalan plus 20 mg/d prednisone for 4 weeks (MP regime) is one of the most commonly used treatments and is believed to inhibit the production and deposition of amyloid. [8] In the present study, only 1 patients were treated with the MP regimen with good results. Kyle et al. [16] treated patients with primary systemic amyloidosis with colchicine (n = 72), MP regimen (n = 77), or MP regimen in combination with colchicine (n = 71) and reported median survival times of 8.5 months, 18 months, and 17 months, respectively.
The primary limitation of this study is its retrospective nature. However, amyloidosis involving only the respiratory system is very rare and this report is of a relatively large number of patients.
Conclusions
In summary, isolated pulmonary amyloidosis is a rarely seen disease and its manifestation are numerous making diagnosis challenging. A high index of suspicion is required to arrive at a prompt diagnosis. Outcomes are varied, and surgical removal of lesions and chemotherapy can be effective.
